Outcomes of Liver Transplant for Adults With Wilson’s Disease

2020 ◽  
Vol 26 (4) ◽  
pp. 507-516 ◽  
Author(s):  
Alberto Ferrarese ◽  
Maria Cristina Morelli ◽  
Paola Carrai ◽  
Martina Milana ◽  
Mario Angelico ◽  
...  
2018 ◽  
Vol 24 (9) ◽  
pp. 1186-1198 ◽  
Author(s):  
Eva-Doreen Pfister ◽  
André Karch ◽  
René Adam ◽  
Wojciech G. Polak ◽  
Vincent Karam ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Talal Hilal ◽  
R. Scott Morehead

New-onset jaundice can be a manifestation of multiple pathologic processes including hemolysis, parenchymal liver disease, and cholestasis; the differential diagnosis is broad and requires a systematic approach. We report a case of a patient who presented with jaundice after starting minocycline for the treatment of acne vulgaris and rapidly developed fulminant liver failure found to be due to Wilson’s disease. She also manifested severe Coomb’s negative hemolytic anemia and renal failure secondary to hepatorenal syndrome. As a bridge to liver transplant, she was successfully treated with plasmapheresis to decrease serum copper in addition to hemodialysis for acidosis and hyperkalemia. She was able to receive a liver and made a full recovery. The case highlights the use of plasmapheresis as an adjunctive treatment modality in cases of fulminant liver failure due to Wilson’s disease.


2011 ◽  
Vol 16 (3) ◽  
pp. 268-275 ◽  
Author(s):  
Abbe G. Boeka ◽  
Andrea C. Solomon ◽  
Kristine Lokken ◽  
Brendan M. McGuire ◽  
J. Steve Bynon

2021 ◽  
Vol 37 (2) ◽  
Author(s):  
Agnieszka Antos ◽  
Tomasz Litwin ◽  
Marta Skowrońska ◽  
Iwona Kurkowska-Jastrzębska ◽  
Anna Członkowska

Objectives. Wilson’s disease (WD) is a genetic, neurodegenerative disorder caused by copper metabolism disturbances with subsequent pathological copper accumulation in organs and tissues (mainly liver and brain) with their secondary damage and clinical symptoms related to affected organs. The treatment of the disease is based on medications leading to negative body copper balance, i.e. (1) decreasing absorption of copper from the digestive tract (zinc salts); (2) increasing the copper excretion with urine (chelators: d-penicillamine, trientine, dimercaprol); and (3) liver transplant in specific clinical situations (acute liver failure, liver cirrhosis decompensation despite treatment). The article aims to review the available literature concerning the current research directions in WD treatment. Literature review. During the space of last years, intensive research into the new treatment of WD has started, including: (1) new pharmacological agents (modified thermostable trientine, trientine with delivery system to central nervous system, molybdenum salts, methanobactin, and others); (2) gene therapy; and (3) cells therapy (hepatocytes transplant). We conducted a targeted literature review of PubMed articles written in English, using the following search terms: “Wilson’s disease,” “treatment perspectives,” and “gene therapy.” Reviews, original articles, randomised controlled trials, meta-analyses, book chapters, and abstracts published up to April 2021 were included. Below, we present a narrative synthesis of the extracted data. Conclusions. Currently, chelators, medications decreasing absorption of copper from the digestive tract, and liver transplant are the treatment methods recommended by international societies as a WD treatment. Among the studies on new therapies for WD, the research with tetrathiomolybdate bis-choline is the most advanced and promising. Great hope can be associated with gene therapy.


2008 ◽  
Vol 20 (4) ◽  
pp. 501-502 ◽  
Author(s):  
Sunny T. Varghese ◽  
Dinesh Narayanan ◽  
Deepa Dinesh

Author(s):  
Somashekara Hosaagrahara Ramakrishna ◽  
Mohan Babu Kasala ◽  
Karnan Perumal ◽  
Selvakumar Malleeswaran ◽  
Rajanikanth V. Patcha ◽  
...  

2000 ◽  
Vol 37 (2) ◽  
pp. 187-189 ◽  
Author(s):  
P Luca ◽  
L Demelia ◽  
S Lecca ◽  
R Ambu ◽  
G Faa

Sign in / Sign up

Export Citation Format

Share Document